Abstract
Summary
Angiotensin II receptor antagonists are a group of pharmaceuticals that modulate the renin–angiotensin system. Their main uses are in the treatment of hypertension (high blood pressure), diabetic nephropathy (kidney damage due to diabetes) and congestive heart failure. They block the activation of AT1receptors, preventing the binding of angiotensin II.
LPI (LP Information)' newest research report, the “Angiotensin Receptor Antagonists Industry Forecast” looks at past sales and reviews total world Angiotensin Receptor Antagonists sales in 2022, providing a comprehensive analysis by region and market sector of projected Angiotensin Receptor Antagonists sales for 2023 through 2029. With Angiotensin Receptor Antagonists sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Angiotensin Receptor Antagonists industry.
This Insight Report provides a comprehensive analysis of the global Angiotensin Receptor Antagonists landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Angiotensin Receptor Antagonists portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Angiotensin Receptor Antagonists market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Angiotensin Receptor Antagonists and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Angiotensin Receptor Antagonists.
The global Angiotensin Receptor Antagonists market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Angiotensin Receptor Antagonists is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Angiotensin Receptor Antagonists is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Angiotensin Receptor Antagonists is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Angiotensin Receptor Antagonists players cover Pfizer, Novartis, Merck, Astra Zeneca, Jhonson and Johnson, Eli Lilly, Sanofi, Bristol-Myers Squibb and Bayer, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Angiotensin Receptor Antagonists market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Valsartan
Telmisartan
Losartan
Irbesartan
Azilsartan
Olmesartan
Segmentation by application
Hypertension
Cardiovascular Diseases
Kidney Diseases
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Novartis
Merck
Astra Zeneca
Jhonson and Johnson
Eli Lilly
Sanofi
Bristol-Myers Squibb
Bayer
GSK
Teva Pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Angiotensin Receptor Antagonists market?
What factors are driving Angiotensin Receptor Antagonists market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Angiotensin Receptor Antagonists market opportunities vary by end market size?
How does Angiotensin Receptor Antagonists break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
LPI (LP Information)' newest research report, the “Angiotensin Receptor Antagonists Industry Forecast” looks at past sales and reviews total world Angiotensin Receptor Antagonists sales in 2022, providing a comprehensive analysis by region and market sector of projected Angiotensin Receptor Antagonists sales for 2023 through 2029. With Angiotensin Receptor Antagonists sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Angiotensin Receptor Antagonists industry.
This Insight Report provides a comprehensive analysis of the global Angiotensin Receptor Antagonists landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Angiotensin Receptor Antagonists portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Angiotensin Receptor Antagonists market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Angiotensin Receptor Antagonists and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Angiotensin Receptor Antagonists.
The global Angiotensin Receptor Antagonists market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Angiotensin Receptor Antagonists is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Angiotensin Receptor Antagonists is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Angiotensin Receptor Antagonists is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Angiotensin Receptor Antagonists players cover Pfizer, Novartis, Merck, Astra Zeneca, Jhonson and Johnson, Eli Lilly, Sanofi, Bristol-Myers Squibb and Bayer, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Angiotensin Receptor Antagonists market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Valsartan
Telmisartan
Losartan
Irbesartan
Azilsartan
Olmesartan
Segmentation by application
Hypertension
Cardiovascular Diseases
Kidney Diseases
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Novartis
Merck
Astra Zeneca
Jhonson and Johnson
Eli Lilly
Sanofi
Bristol-Myers Squibb
Bayer
GSK
Teva Pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Angiotensin Receptor Antagonists market?
What factors are driving Angiotensin Receptor Antagonists market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Angiotensin Receptor Antagonists market opportunities vary by end market size?
How does Angiotensin Receptor Antagonists break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Angiotensin Receptor Antagonists Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Angiotensin Receptor Antagonists by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Angiotensin Receptor Antagonists by Country/Region, 2018, 2022 & 2029
2.2 Angiotensin Receptor Antagonists Segment by Type
2.2.1 Valsartan
2.2.2 Telmisartan
2.2.3 Losartan
2.2.4 Irbesartan
2.2.5 Azilsartan
2.2.6 Olmesartan
2.3 Angiotensin Receptor Antagonists Sales by Type
2.3.1 Global Angiotensin Receptor Antagonists Sales Market Share by Type (2018-2023)
2.3.2 Global Angiotensin Receptor Antagonists Revenue and Market Share by Type (2018-2023)
2.3.3 Global Angiotensin Receptor Antagonists Sale Price by Type (2018-2023)
2.4 Angiotensin Receptor Antagonists Segment by Application
2.4.1 Hypertension
2.4.2 Cardiovascular Diseases
2.4.3 Kidney Diseases
2.4.4 Other
2.5 Angiotensin Receptor Antagonists Sales by Application
2.5.1 Global Angiotensin Receptor Antagonists Sale Market Share by Application (2018-2023)
2.5.2 Global Angiotensin Receptor Antagonists Revenue and Market Share by Application (2018-2023)
2.5.3 Global Angiotensin Receptor Antagonists Sale Price by Application (2018-2023)
3 Global Angiotensin Receptor Antagonists by Company
3.1 Global Angiotensin Receptor Antagonists Breakdown Data by Company
3.1.1 Global Angiotensin Receptor Antagonists Annual Sales by Company (2018-2023)
3.1.2 Global Angiotensin Receptor Antagonists Sales Market Share by Company (2018-2023)
3.2 Global Angiotensin Receptor Antagonists Annual Revenue by Company (2018-2023)
3.2.1 Global Angiotensin Receptor Antagonists Revenue by Company (2018-2023)
3.2.2 Global Angiotensin Receptor Antagonists Revenue Market Share by Company (2018-2023)
3.3 Global Angiotensin Receptor Antagonists Sale Price by Company
3.4 Key Manufacturers Angiotensin Receptor Antagonists Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Angiotensin Receptor Antagonists Product Location Distribution
3.4.2 Players Angiotensin Receptor Antagonists Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Angiotensin Receptor Antagonists by Geographic Region
4.1 World Historic Angiotensin Receptor Antagonists Market Size by Geographic Region (2018-2023)
4.1.1 Global Angiotensin Receptor Antagonists Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Angiotensin Receptor Antagonists Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Angiotensin Receptor Antagonists Market Size by Country/Region (2018-2023)
4.2.1 Global Angiotensin Receptor Antagonists Annual Sales by Country/Region (2018-2023)
4.2.2 Global Angiotensin Receptor Antagonists Annual Revenue by Country/Region (2018-2023)
4.3 Americas Angiotensin Receptor Antagonists Sales Growth
4.4 APAC Angiotensin Receptor Antagonists Sales Growth
4.5 Europe Angiotensin Receptor Antagonists Sales Growth
4.6 Middle East & Africa Angiotensin Receptor Antagonists Sales Growth
5 Americas
5.1 Americas Angiotensin Receptor Antagonists Sales by Country
5.1.1 Americas Angiotensin Receptor Antagonists Sales by Country (2018-2023)
5.1.2 Americas Angiotensin Receptor Antagonists Revenue by Country (2018-2023)
5.2 Americas Angiotensin Receptor Antagonists Sales by Type
5.3 Americas Angiotensin Receptor Antagonists Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Angiotensin Receptor Antagonists Sales by Region
6.1.1 APAC Angiotensin Receptor Antagonists Sales by Region (2018-2023)
6.1.2 APAC Angiotensin Receptor Antagonists Revenue by Region (2018-2023)
6.2 APAC Angiotensin Receptor Antagonists Sales by Type
6.3 APAC Angiotensin Receptor Antagonists Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Angiotensin Receptor Antagonists by Country
7.1.1 Europe Angiotensin Receptor Antagonists Sales by Country (2018-2023)
7.1.2 Europe Angiotensin Receptor Antagonists Revenue by Country (2018-2023)
7.2 Europe Angiotensin Receptor Antagonists Sales by Type
7.3 Europe Angiotensin Receptor Antagonists Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Angiotensin Receptor Antagonists by Country
8.1.1 Middle East & Africa Angiotensin Receptor Antagonists Sales by Country (2018-2023)
8.1.2 Middle East & Africa Angiotensin Receptor Antagonists Revenue by Country (2018-2023)
8.2 Middle East & Africa Angiotensin Receptor Antagonists Sales by Type
8.3 Middle East & Africa Angiotensin Receptor Antagonists Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Angiotensin Receptor Antagonists
10.3 Manufacturing Process Analysis of Angiotensin Receptor Antagonists
10.4 Industry Chain Structure of Angiotensin Receptor Antagonists
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Angiotensin Receptor Antagonists Distributors
11.3 Angiotensin Receptor Antagonists Customer
12 World Forecast Review for Angiotensin Receptor Antagonists by Geographic Region
12.1 Global Angiotensin Receptor Antagonists Market Size Forecast by Region
12.1.1 Global Angiotensin Receptor Antagonists Forecast by Region (2024-2029)
12.1.2 Global Angiotensin Receptor Antagonists Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Angiotensin Receptor Antagonists Forecast by Type
12.7 Global Angiotensin Receptor Antagonists Forecast by Application
13 Key Players Analysis
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Angiotensin Receptor Antagonists Product Portfolios and Specifications
13.1.3 Pfizer Angiotensin Receptor Antagonists Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Novartis
13.2.1 Novartis Company Information
13.2.2 Novartis Angiotensin Receptor Antagonists Product Portfolios and Specifications
13.2.3 Novartis Angiotensin Receptor Antagonists Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Novartis Main Business Overview
13.2.5 Novartis Latest Developments
13.3 Merck
13.3.1 Merck Company Information
13.3.2 Merck Angiotensin Receptor Antagonists Product Portfolios and Specifications
13.3.3 Merck Angiotensin Receptor Antagonists Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Merck Main Business Overview
13.3.5 Merck Latest Developments
13.4 Astra Zeneca
13.4.1 Astra Zeneca Company Information
13.4.2 Astra Zeneca Angiotensin Receptor Antagonists Product Portfolios and Specifications
13.4.3 Astra Zeneca Angiotensin Receptor Antagonists Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Astra Zeneca Main Business Overview
13.4.5 Astra Zeneca Latest Developments
13.5 Jhonson and Johnson
13.5.1 Jhonson and Johnson Company Information
13.5.2 Jhonson and Johnson Angiotensin Receptor Antagonists Product Portfolios and Specifications
13.5.3 Jhonson and Johnson Angiotensin Receptor Antagonists Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Jhonson and Johnson Main Business Overview
13.5.5 Jhonson and Johnson Latest Developments
13.6 Eli Lilly
13.6.1 Eli Lilly Company Information
13.6.2 Eli Lilly Angiotensin Receptor Antagonists Product Portfolios and Specifications
13.6.3 Eli Lilly Angiotensin Receptor Antagonists Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Eli Lilly Main Business Overview
13.6.5 Eli Lilly Latest Developments
13.7 Sanofi
13.7.1 Sanofi Company Information
13.7.2 Sanofi Angiotensin Receptor Antagonists Product Portfolios and Specifications
13.7.3 Sanofi Angiotensin Receptor Antagonists Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Sanofi Main Business Overview
13.7.5 Sanofi Latest Developments
13.8 Bristol-Myers Squibb
13.8.1 Bristol-Myers Squibb Company Information
13.8.2 Bristol-Myers Squibb Angiotensin Receptor Antagonists Product Portfolios and Specifications
13.8.3 Bristol-Myers Squibb Angiotensin Receptor Antagonists Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Bristol-Myers Squibb Main Business Overview
13.8.5 Bristol-Myers Squibb Latest Developments
13.9 Bayer
13.9.1 Bayer Company Information
13.9.2 Bayer Angiotensin Receptor Antagonists Product Portfolios and Specifications
13.9.3 Bayer Angiotensin Receptor Antagonists Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Bayer Main Business Overview
13.9.5 Bayer Latest Developments
13.10 GSK
13.10.1 GSK Company Information
13.10.2 GSK Angiotensin Receptor Antagonists Product Portfolios and Specifications
13.10.3 GSK Angiotensin Receptor Antagonists Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 GSK Main Business Overview
13.10.5 GSK Latest Developments
13.11 Teva Pharmaceutical
13.11.1 Teva Pharmaceutical Company Information
13.11.2 Teva Pharmaceutical Angiotensin Receptor Antagonists Product Portfolios and Specifications
13.11.3 Teva Pharmaceutical Angiotensin Receptor Antagonists Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Teva Pharmaceutical Main Business Overview
13.11.5 Teva Pharmaceutical Latest Developments
14 Research Findings and Conclusion